Dr. Reddy’s (RDY) Laboratories is still awaiting approval for Semaglutide in Canada, sources with knowledge of the matter told CNBC-TV18’s Ekta Batra. Analysts who track Dr. Reddy’s expect six to nine months of no competition in the Canadian market, the report noted. Semaglutide is a GLP-1 receptor agonist primarily used for treating Type 2 diabetes and chronic weight management that is sold under brand names Ozempic, Wegovy, and Rybelsus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s rally on CNBC report overstates upside, says Citi
- Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure
- Dr. Reddy’s Divests Svaas Wellness Subsidiary in Small April 2026 Deal
- Dr. Reddy’s Allots Equity Shares Under ESOP on March 26, 2026
- Dr. Reddy’s Tightens Insider-Information Disclosure Code After Board Approval